Atossa Therapeutics Announces First Quarter 2024 Financial globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Sunday a fundraising event was held at Mia Via Restaurant and Bar in Luzerne for Courtney Keezer who was diagnosed with Stage 2 Invasive Ductal Carcinoma, a for
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R